Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx
布朗克斯区注重多样性的蒙特菲奥里·爱因斯坦临床肿瘤学培训项目
基本信息
- 批准号:10646803
- 负责人:
- 金额:$ 2.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:Albert Einstein Cancer CenterBasic ScienceBiometryCancer CenterCatchment AreaClinical InvestigatorClinical OncologyClinical ResearchClinical TrialsCommunity OutreachDevelopmentDisciplineDoctor of MedicineDoctor of PhilosophyEcosystemEducational CurriculumEducational workshopEnrollmentEquityEvaluationFundingGoalsGrantImmunotherapyInstitutionInvestigational TherapiesK-Series Research Career ProgramsLeadershipLiquid substanceMalignant NeoplasmsMedicineMentored Clinical Scientist Development ProgramMentorsMinorityMinority GroupsModelingOncologyOutcomeParticipantPopulationPopulation HeterogeneityPositioning AttributePrincipal InvestigatorPublicationsQualifyingResearchResearch MethodologyResearch PersonnelResearch Project GrantsSolid NeoplasmTherapeuticTherapeutic ResearchTrainingTraining ProgramsTranslational ResearchWagesWritingcancer carecancer research center directorcare deliverycareercommunity engagementcomparative effectivenessdesignmedical schoolsnext generationnovelpatient orientedprogramsrecruitsenior facultytranslational scientistunderserved minority
项目摘要
Project Abstract
The goal of Einstein/Montefiore Paul Calabresi Career Development Award for Clinical Oncology and Equity
Research is to train the next generation of oncology scholars, with a special emphasis on conducting clinical and
translational research in the underserved and diverse Bronx catchment area. This will be achieved through a
coordinated program of mentoring, a comprehensive formal curriculum, and research projects with an
interdisciplinary, collaborative design with focus on community outreach and engagement. The program, its
leadership and participants are integrated within the established research programs of the NCI-designated
Montefiore Einstein Cancer Center (AECC). The Calabresi Program will select highly qualified clinical and
translational investigators from all oncology disciplines, from a diverse group of primarily MDs, but also PhDs,
who are committed to careers in patient-oriented clinical and translational research with a focus on diverse
populations. The duration of the training is 2 to 3 years and funding for 4 scholars is requested. The research
focus is being expanded beyond cancer therapeutics to include cancer care delivery relevant to the Bronx
population, which is 70% URM’s. A formal curriculum has been developed in conjunction with Einstein’s Institute
for Clinical and Translational Research (ICTR) featuring an MS degree in Clinical Research Methods and
includes two mandatory Calabresi-centered courses, one on “Clinical Trial Development in the Era of
Personalized Cancer Medicine and Immunotherapy”, and another on “Comparative Effectiveness Therapeutic
Research”. Additional courses and workshops are offered in Biostatistics and Grant writing. The Principal
Investigators are Dr. Amit Verma, M.D., Director of the Division of Hemato-Oncology, and Dr. Yvonne Saenger,
MD, Director of the Immunotherapy program and Coleader of Experimental Therapeutics. Both PIs bring
complementary expertise in both liquid and solid tumors and also a track-recordin basic/translational and clinical
research, as well as in mentoring junior clinical investigators. An Executive Committee of senior faculty leaders
provide oversight in the selection and ongoing evaluation of the progress of the Scholars and the impact of the
program. An Internal Advisory Board (IAB) chaired by cancer center director, Dr. Edward Chu, and an External
Advisory Board with K12 PIs will provide guidance and direction to the Calabresi program. Novel initiatives are
planned to increase the recruitment of URM candidates. Strong institutional support from the Medical College,
Cancer Center and Montefiorehas resultedin salary support of numerous scholars. Since inception, the Program
has enrolled 24 Scholars (3 URMs): with 22 remaining committed to academic careers in leadership positions in
oncology. A successful track record of high impact publications, especially in fields of minority outcomes in
diverse populations of the Bronx is evidence of uniqueness of the proposed training program. Our proposed K12
training grant will train the next generation of oncology clinical researchers on unique challenges of conducting
successful clinical trials in underserved minority populations, using the Bronx as a model ecosystem.
项目摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yvonne Margaret Saenger其他文献
Yvonne Margaret Saenger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yvonne Margaret Saenger', 18)}}的其他基金
A prognostic mRNA immune signature for resected stage II-III melanoma
切除的 II-III 期黑色素瘤的预后 mRNA 免疫特征
- 批准号:
10609514 - 财政年份:2019
- 资助金额:
$ 2.57万 - 项目类别:
A prognostic mRNA immune signature for resected stage II-III melanoma
切除的 II-III 期黑色素瘤的预后 mRNA 免疫特征
- 批准号:
10412153 - 财政年份:2019
- 资助金额:
$ 2.57万 - 项目类别:
Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)
内镜下给予 T-Vec 治疗晚期胰腺癌的第一阶段研究 IN 17248 (11/21/2016)
- 批准号:
10001349 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别:
Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)
内镜下给予 T-Vec 治疗晚期胰腺癌的第一阶段研究 IN 17248 (11/21/2016)
- 批准号:
9751220 - 财政年份:2018
- 资助金额:
$ 2.57万 - 项目类别:
相似海外基金
HNDS-R: Connectivity, Inclusiveness, and the Permeability of Basic Science
HNDS-R:基础科学的连通性、包容性和渗透性
- 批准号:
2318404 - 财政年份:2023
- 资助金额:
$ 2.57万 - 项目类别:
Standard Grant
Advancing the basic science of membrane permeability in macrocyclic peptides
推进大环肽膜渗透性的基础科学
- 批准号:
10552484 - 财政年份:2023
- 资助金额:
$ 2.57万 - 项目类别:
Computer Vision for Malaria Microscopy: Automated Detection and Classification of Plasmodium for Basic Science and Pre-Clinical Applications
用于疟疾显微镜的计算机视觉:用于基础科学和临床前应用的疟原虫自动检测和分类
- 批准号:
10576701 - 财政年份:2023
- 资助金额:
$ 2.57万 - 项目类别:
Bringing together communities and basic science researchers to build stronger relationships
将社区和基础科学研究人员聚集在一起,建立更牢固的关系
- 批准号:
480914 - 财政年份:2023
- 资助金额:
$ 2.57万 - 项目类别:
Miscellaneous Programs
“L-form” bacteria: basic science, antibiotics, evolution and biotechnology
L 型细菌:基础科学、抗生素、进化和生物技术
- 批准号:
FL210100071 - 财政年份:2022
- 资助金额:
$ 2.57万 - 项目类别:
Australian Laureate Fellowships
Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions
早期病变转化和基础科学研究协调和数据管理中心
- 批准号:
10517004 - 财政年份:2022
- 资助金额:
$ 2.57万 - 项目类别:
Developing science communication on large scale basic science represented by accelerator science
发展以加速器科学为代表的大规模基础科学科学传播
- 批准号:
22K02974 - 财政年份:2022
- 资助金额:
$ 2.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Science Core - Biosafety & Biocontainment Core (BBC)
基础科学核心 - 生物安全
- 批准号:
10431468 - 财政年份:2022
- 资助金额:
$ 2.57万 - 项目类别:














{{item.name}}会员




